Eventide Asset Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Eventide Asset Management’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$21M	Buy	1,513,958 +810	+0.1%	+$11.4K	0.35%	101
2025 Q4	$18.3M	Buy	1,513,148 +648	+0%	+$8.8K	0.29%	107
2025 Q3	$20.6M	Buy	+1,512,500	New	+$14.2M	0.34%	95
2024 Q1	–	Sell	-1,116,837	Closed	-$16.4M	–	160
2023 Q4	$16.4M	Hold	1,116,837	–	–	0.27%	97
2023 Q3	$20.4M	Hold	1,116,837	–	–	0.37%	81
2023 Q2	$24.1M	Buy	1,116,837 +658,783	+144%	+$17.8M	0.41%	76
2023 Q1	$13.4M	Buy	458,054 +208,054	+83%	+$7.23M	0.25%	109
2022 Q4	$9.24M	Buy	+250,000	New	+$8.87M	0.18%	110

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Eventide Asset Management's AMLX Position: Q1 2026 in Review

Eventide Asset Management increased its Amylyx Pharmaceuticals (AMLX) stake by 0.05% in Q1 2026, buying an estimated $11.4K and bringing the position to 1,513,958 shares worth $21M. The position accounts for 0.35% of the portfolio, ranked #101.

Eventide Asset Management first reported a position in AMLX in Q4 2022 and has held it in 8 quarters since. The position peaked at $24.1M in Q2 2023. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

Eventide Asset Management held 1,513,958 shares of Amylyx Pharmaceuticals worth $21M as of Q1 2026.
Eventide Asset Management bought 810 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $11.4K.
Amylyx Pharmaceuticals made up 0.35% of Eventide Asset Management's portfolio in Q1 2026, its #101 holding.
Eventide Asset Management first reported a position in Amylyx Pharmaceuticals in Q4 2022 and has held it in 8 quarters since.
Eventide Asset Management's Amylyx Pharmaceuticals position peaked at $24.1M in Q2 2023.
171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Eventide Asset Management's 13F filing for Q1 2026, filed 15 May 2026.